Overcoming Resistance: The Challenge and Innovation in Her2 Positive Breast Cancer Treatment The landscape for treating Her2-positive breast cancer has been dramatically reshaped by the emergence of Antibody-Drug Conjugates (ADCs), which represent a sophisticated evolution of targeted therapy. ADCs, such as trastuzumab deruxtecan (T-DXd), operate by linking a highly potent chemotherapy agent to a monoclonal antibody. The antibody specifically targets and binds to the Her2 receptor on...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
